PLACEMENT AGENT WARRANT BIOAFFINITY TECHNOLOGIES, INC.bioAffinity Technologies, Inc. • October 21st, 2024 • Services-commercial physical & biological research • New York
Company FiledOctober 21st, 2024 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 21, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October 20, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 21st, 2024 • bioAffinity Technologies, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledOctober 21st, 2024 Company Industry JurisdictionTHIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of October 18, 2024, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 21st, 2024 • bioAffinity Technologies, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledOctober 21st, 2024 Company Industry Jurisdiction
SUPPORT AGREEMENTSupport Agreement • October 21st, 2024 • bioAffinity Technologies, Inc. • Services-commercial physical & biological research
Contract Type FiledOctober 21st, 2024 Company IndustryThis SUPPORT AGREEMENT (this “Agreement”) is made as of October 21, 2024, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”).